细菌的抗生素耐药已经成为日益严峻的全球性公共卫生问题。新抗菌药物研发的缓慢，进一步加剧了这种困境。本项目拟整合上海同步辐射光源大科学装置、上海药物所的抗菌感染新药研究平台、英国Diamond光源的FBLD技术平台，以及英国邓迪大学和牛津大学等抗感染药物化学研究平台，发展FBLD技术平台并运用于抗菌新药的发现研究。主要针对细菌的细胞壁、蛋白质生物合成以及细菌的致病力（或毒力）等相关的候选靶标开发新类型的抗菌候选药物。本合作项目将进一步深化中英两国科学家之间的知识和技术交流，加速国内基于FBLD技术的抗菌新药研究进展，促进针对年青一代科研人员的跨国高科技培训体系和科研环境的建设。

The high prevalence of multi-resistant bacteria pathogens is real threat to human health worldwide. To make matter worse, the drug-discovery pipeline of new antibacterial is almost empty. The synchrotrons at Shanghai and the Drug Discovery unit at Shanghai Institute of Materia Medica are powerful technology hubs. However, there are few researchers in China (and even worldwide) engaged in structurally informed antibacterial drug discovery. In particular Diamond Light Source at Harwell (UK) has a state of the art automated beam line dedicated to high throughput fragment based lead discovery (FBLD) and Dundee expertise in medicinal chemistry for anti-infective drug discovery. We plan to integrate these hubs with AMR centres of excellence in China and the UK, deliver state of the art training to these researchers and exploit FBLD capabilities to identify novel chemical probes. These new chemical probes, alongside high throughput structural biology and mechanistic insight, will all importantly, accelerate the validation of novel virulence AMR targets by providing the structural insight to build new effective inhibitors for these, and inhibitor discovery for well validated targets in cell wall and protein biosynthesis. This collaboration will establish knowledge and technology transfer between China and UK research groups to accelerate antibiotic discovery in China, and establish a high-tech trans-national training environment for the next generation of researchers who are dedicated to involve in high profile AMR funded projects in China and UK.